The table below shows Apellis Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$1.00B
$781.37M
$396.59M
$75.42M
$66.56M
$250.65M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$295.85M
$327.57M
$354.39M
$387.24M
$345.87M
$299.92M
SG&A
APLS annual revenue (10-K history)
Apellis Pharmaceuticals, Inc. reported annual revenue of $1.00B for fiscal year 2025. That is up 28.5% from $781.37M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $250.65M (FY 2020) to $1.00B. Figures come from the company's audited annual reports as filed with the SEC.